Analysis of bowel obstruction and ileus events in GLP-1 drug users evaluates this safety signal using clinical data and pharmacovigilance reports.
Key findingAnalysis of bowel obstruction and ileus events in GLP-1 drug users evaluates this safety signal usin
What the researchers found
Analysis of bowel obstruction and ileus events in GLP-1 drug users evaluates this safety signal using clinical data and pharmacovigilance reports.
Why it matters
These findings are relevant to the growing population of patients using or considering peptide-based therapies.
The numbers in context
317 records screened. Meta-analysis included RCTs and observational studies. No statistically significant increase in bowel obstruction or ileus found.
How the study worked
Study design and methodology detailed in the full publication.
Who was studied
Adults taking GLP-1 receptor agonists across RCTs, cohort studies, and case reports
What this study cannot tell us
Study limitations discussed in the full publication.
How to read the evidence
Evidence assessment based on study design in publication.
When this study was published
Published in 2025.
The bigger picture
This study contributes to the expanding evidence for peptide-based therapeutics in clinical medicine.
Questions still open
- What are the long-term implications?
- How do results compare to existing evidence?
- What further research is needed?
Common questions
What does this study mean for patients?
How reliable are these findings?
Read the original research
Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis.
Expert opinion on drug safety, 1-9
Citation
Alfehaid, Lama; Alyami, Majed; Almohareb, Sumaya; Alshaya, Omar; Almutairi, Abdulaali. (2025). Evaluating bowel obstruction and ileus events in patients on GLP-1 receptor agonists: a systematic review and meta-analysis.. Expert opinion on drug safety, 1-9. https://doi.org/10.1080/14740338.2025.2465870